München
06.02.26 | 08:00
1,624 Euro
-2,05 % -0,034
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.01. | DIAMYD MEDICAL AB: Quarterly Report 1 25/26 | 3 | Cision News | ||
| 28.01. | Diamyd Medical AB (publ): Quarterly Report 1 25/26 | 79 | GlobeNewswire (Europe) | September 2025 - November 2025 Diamyd Medical AB (publ), Fiscal year 2025/2026
Precision Medicine for type 1 diabetes
Aiming for Accelerated Market Approval
Diamyd Medical develops a proprietary platform... ► Artikel lesen | |
| 23.01. | DIAMYD MEDICAL AB: Diamyd Medical deepens long-term manufacturing collaboration for retogatein | 1 | Cision News | ||
| 23.01. | Diamyd Medical AB (publ): Diamyd Medical deepens long-term manufacturing collaboration for retogatein | 167 | GlobeNewswire (Europe) | Diamyd Medical is taking the next step in a long-term manufacturing collaboration with APL and, in parallel, is initiating a strategic collaboration with NorthX Biologics to further develop and scale... ► Artikel lesen | |
| 12.01. | DIAMYD MEDICAL AB: Diamyd Medical announces completion of screening in pivotal Phase 3 DIAGNODE-3 trial | 4 | Cision News | ||
| 12.01. | Diamyd Medical AB (publ): Diamyd Medical announces completion of screening in pivotal Phase 3 DIAGNODE-3 trial | 121 | GlobeNewswire (Europe) | Diamyd Medical today announced that the screening period in its pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals with type 1 diabetes has been completed. Based on the... ► Artikel lesen | |
| 09.01. | DIAMYD MEDICAL AB: Diamyd Medical's lead immunotherapy for type 1 diabetes receives global non-proprietary name retogatein | 4 | Cision News | ||
| 09.01. | Diamyd Medical AB (publ): Diamyd Medical's lead immunotherapy for type 1 diabetes receives global non-proprietary name retogatein | 113 | GlobeNewswire (Europe) | Diamyd Medical today announced that its investigational antigen-specific immunotherapy for type 1 diabetes, commonly referred to as Diamyd, has been assigned the global non-proprietary name "retogatein"... ► Artikel lesen | |
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 29.12.25 | Diamyd Medical Secures FDA Alignment To Accelerate Phase 3 Trial Readout In Type 1 Diabetes | 1 | RTTNews | ||
| 29.12.25 | Diamyd Medical AB: Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes Phase 3 trial following FDA alignment and guidance | 326 | PR Newswire | STOCKHOLM, Dec. 29, 2025 /PRNewswire/ -- Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal... ► Artikel lesen | |
| 12.12.25 | Diamyd Medical AB (publ): Diamyd Medical finalizing Phase 3 screening as GMP review progresses | 168 | GlobeNewswire (Europe) | The number of randomized participants in DIAGNODE-3, Diamyd Medical's registrational Phase 3 trial in type 1 diabetes, has now exceeded 290, and the screening will conclude in the coming weeks. The... ► Artikel lesen | |
| 04.12.25 | Bulletin from Annual General Meeting of Diamyd Medical AB | 2 | Cision News | ||
| 02.12.25 | DIAMYD MEDICAL AB: Annual Report 2024/2025 | 5 | Cision News | ||
| 14.11.25 | Diamyd Medical AB: Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears last safety review ahead of early readout in March 2026 | 609 | PR Newswire | STOCKHOLM, Nov. 14, 2025 /PRNewswire/ -- The independent Data Safety Monitoring Board (DSMB) has completed its sixth scheduled safety review of Diamyd Medical's registrational Phase... ► Artikel lesen | |
| 13.11.25 | Diamyd Medical AB Ser. B Full Year Sales Decline | 1 | RTTNews | ||
| 13.11.25 | DIAMYD MEDICAL AB: Information about the Annual Report 2024/2025 | 1 | Cision News | ||
| 12.11.25 | DIAMYD MEDICAL AB: Diamyd Medical marks World Diabetes Day with expert panel on the future of Type 1 Diabetes treatment | 3 | Cision News | ||
| 08.10.25 | Diamyd Medical AB Ser. B Q4 Loss Widens | - | RTTNews | ||
| 08.10.25 | DIAMYD MEDICAL AB: Year-End Report 24/25 | 1 | Cision News | ||
| 08.10.25 | Diamyd Medical AB (publ): Year-End Report 24/25 | 255 | GlobeNewswire (Europe) | September 2024 - August 2025, Diamyd Medical AB (publ), Fiscal year 2024/2025
Precision Medicine for Type 1 Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical develops a proprietary platform... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 45,800 | +2,20 % | Dax - Ausblick auf die neue Handelswoche: Bayer - Wann fällt die Marke von 50 Euro? | Nach einer überaus turbulenten Handelswoche richten sich die Blicke bereits auf die neue Handelswoche und damit auf den neuen Monat. Der Januar gestaltete sich für den Dax durchaus ambivalent. Dem Index... ► Artikel lesen | |
| NOVO NORDISK | 40,310 | +0,01 % | Abnehmpille schlägt ein: Starker Start ins neue Jahr - Novo Nordisk zeigt Eli Lilly die Rücklichter! | © Foto: Kristian Tuxen Ladegaard Berg - NurPhotoNach einem schwachen Vorjahr meldet sich Novo Nordisk 2026 eindrucksvoll zurück. Die neue Wegovy-Tablette sorgt in den USA für einen starken Marktstart.... ► Artikel lesen | |
| PFIZER | 23,015 | -0,07 % | Opening Bell: Gold/Silber, PepsiCo, Merck & Co, Pfizer, PayPal, Teradyne, Uber/Snap/Alphabet, Nvidia | Die US-Börsen sind zum Wochenstart fester aus dem Handel gegangen. Der Dow Jones gewann 1,05 Prozent, der Nasdaq Composite legte 0,56 Prozent zu. Am Freitag hatte die mögliche Nominierung von Kevin... ► Artikel lesen | |
| GILEAD SCIENCES | 128,98 | -0,05 % | Gilead wins favorable U.S. label update for Yescarta | ||
| ABBVIE | 189,20 | +0,11 % | Aktien New York Ausblick: Keine Tech-Erholung - Eli Lilly steigen kräftig | NEW YORK (dpa-AFX) - Mit Blick auf den Technologiesektor dürften sich die Investoren an den US-Börsen am Mittwoch zurückhalten. Der Nasdaq 100 Index, der am Vortag deutlich gefallen war, dürfte sich... ► Artikel lesen | |
| ELI LILLY | 894,80 | -0,01 % | Goldman Sachs Reaffirms Buy on Eli Lilly and Company (LLY), Citing 25% Growth Outlook | ||
| ABBOTT LABORATORIES | 93,98 | +0,23 % | Abbott Reports Positive 12-month Results From VOLT-AF IDE Study | NORTH CHICAGO (dpa-AFX) - Abbott (ABT) announced clinical data from two presentations at AF Symposium in Boston that demonstrate the strong safety and efficacy of the company's minimally invasive... ► Artikel lesen | |
| ZOETIS | 108,12 | +0,30 % | Zoetis Inc. - 8-K, Current Report | ||
| NEWRON PHARMACEUTICALS | 20,900 | +0,72 % | EQS-News: Newron Pharmaceuticals S.p.A.: Newron verweist auf eine wissenschaftliche Publikation, welche die klinisch bedeutsamen Vorteile von Evenamide als Zusatzbehandlung bei Schizophrenie hervorhebt | EQS-News: Newron Pharmaceuticals S.p.A.
/ Schlagwort(e): Wissenschaftl. Publikation
Newron verweist auf eine wissenschaftliche Publikation, welche die klinisch bedeutsamen Vorteile... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 152,25 | -1,36 % | Should You Buy Axsome Therapeutics Stock Before Feb. 23? | ||
| DAIICHI SANKYO | 15,995 | +0,25 % | Daiichi Sankyo, AstraZeneca's Datroway Granted FDA Priority Review In Advanced TNBC | LONDON (dpa-AFX) - Daiichi Sankyo Company Limited (DSKYF) and AstraZeneca's (AZN) supplemental Biologics License Application (sBLA) for Datroway has been granted Priority Review by the U.S.... ► Artikel lesen | |
| TRULIEVE CANNABIS | 5,970 | +2,14 % | Trulieve Cannabis Corp.: Trulieve Completes Redemption of All US$368 Million 8.0% Senior Secured Notes due 2026 | TALLAHASSEE, Fla., Dec. 8, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,970 | +0,25 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union | - Company expects to receive a negative opinion following oral explanation feedback and intends to request re-examination upon review of formal adoption.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD)... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,550 | -0,63 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| TG THERAPEUTICS | 24,365 | 0,00 % | TG Therapeutics presents BRIUMVI data at ACTRIMS forum |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -2,05 % bei einem Aktienkurs von 1,624 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.